USClinicalTrials.govClinical trialPhase 3Recruiting
Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer
Official record
- Identifier
NCT07851025- Recruiting locations
countries
United StatesArgentinaAustraliaBrazilBulgariaCanadaChileChinaColombiaGermanyGreeceIndiaIsraelItalyJapanMalaysiaPeruPhilippinesSlovakiaSloveniaSouth KoreaSpainTaiwanThailand- Interventions studied
- Torvutatug samrotecanBevacizumab
- Lead sponsor
- AstraZeneca
- Target enrolment
- 950 participants
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Status
- Recruiting
- First posted
- Oct 1, 2026
- Last updated on the registry
- Oct 1, 2026
- Age
- 18 Years
- Sex
- FEMALE
- Study contact
- The official record lists a study contact. Contact details are published there and are intentionally not copied to this page.
- Eligibility criteria
Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.
Key Inclusion Criteria: * Participants with newly diagnosed FIGO Stage III/IV, histologically confirmed epithelial high-grade ovarian, fallopian tube or primary peritoneal carcinoma * Provision of an archival FFPE tumour sample * Participants who have completed at least 6 cycles and a maximum of 8 cycles of first-line Platinum-based chemotherapy (PBC) prior to randomisation * Participants must have received a minimum of 3 cycles of bevacizumab in combination with the 3 last cycles of PBC, prior to randomisation * Participants who have completed cytoreductive surgery or have inoperable disease * Participants with non-progressive disease upon completion of front-line induction therapy * HRD negative tumour Key Exclusion Criteria: * Participants with tumours of non-epithelial origin, borderline tumours, or low-grade epithelial tumours. * Participants with history of (non-infectious) ILD/pneumonitis that required steroids or supplemental oxygen, or has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at Screening * Participants with non-healing wound, active ulcer, or bone fracture * Participants with evidence of active or ongoing bowel obstruction * Prior exposure to any FRα-targeted therapy, including MIRV, or any TOP1i Antibody-drug Conjugate (ADC)
- Indexed under
- Ovarian Cancer